Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.
Tirzepatide treatment for 12 weeks resulted in an average weight loss of 8.75 kg, primarily from fat mass, with a relative preservation of lean mass.
Where it sits
this study against the rest of the tirzepatide corpusSummary and findings
This study evaluated short-term changes in body composition in 51 adults with obesity treated with tirzepatide for 12 weeks. Body weight decreased by 8.75 kg, primarily due to a reduction in fat mass. The findings suggest a favorable body composition change characterized by fat loss and preservation of lean mass.
Abstract
<h4>Background</h4>Tirzepatide induces substantial weight loss, but real-world data on early body composition changes remain limited.<h4>Methods</h4>We evaluated short-term changes in body composition in 51 adults with obesity treated with tirzepatide for 12 weeks, using bioelectrical impedance analysis.<h4>Results</h4>Body weight decreased by 8.75 kg (-8.18%, P < 0.001), primarily driven by fat mass reduction (-6.87 kg, P < 0.001), with a smaller decrease in soft lean mass (-1.73 kg, P < 0.001). Despite this, the relative proportion of lean mass increased (+3.00 percentage points, P < 0.001), indicating preferential fat loss. Approximately 78% of total weight loss was attributable to fat mass.<h4>Conclusion</h4>These findings suggest that short-term tirzepatide therapy leads to favorable body composition changes, characterized by predominant fat loss and relative preservation of lean mass, supporting its metabolic benefit in real-world clinical practice.
Background
This paper addresses the impact of tirzepatide on body composition in adults with obesity, an area where real-world data is limited. Prior studies have indicated that tirzepatide induces weight loss, but there is a need to understand its effects on body composition specifically. This study is significant as it provides insights into early changes in body composition following tirzepatide treatment.
Methods
The study utilized a real-world design, evaluating 51 adults with obesity who were treated with tirzepatide for 12 weeks. Body composition changes were assessed using bioelectrical impedance analysis. The primary outcome measure was the change in body weight, while secondary measures included changes in fat mass and lean mass.
Results
The primary endpoint showed that body weight decreased by 8.75 kg (-8.18%, P < 0.001) after 12 weeks of treatment. Fat mass was reduced by 6.87 kg (P < 0.001), while soft lean mass decreased by 1.73 kg (P < 0.001). The relative proportion of lean mass increased by 3.00 percentage points (P < 0.001), indicating preferential fat loss.
Interpretation
The findings align with previous literature suggesting that tirzepatide can lead to significant weight loss and favorable body composition changes. However, while the results are statistically significant, the clinical significance of the changes in lean mass may be limited given the small effect size. Confounding factors include the small sample size and the short duration of the study, which may not capture long-term effects.
Key findings
- Body weight decreased by 8.75 kg (-8.18%, P < 0.001)
- Fat mass reduced by 6.87 kg (P < 0.001)
- Soft lean mass decreased by 1.73 kg (P < 0.001)
- Relative proportion of lean mass increased by 3.00 percentage points (P < 0.001)
- Approximately 78% of total weight loss was attributable to fat mass
Limitations
- small sample size n=51
- 12-week follow-up too short to see durability
- real-world study may have uncontrolled variables